FDA approves Bayer's new stroke drug Sunharbo
The FDA has approved Bayer's new drug, Sunharbo, to help prevent recurrent strokes. As the first in a novel class of medications, it targets a specific protein to block dangerous blood clots without increasing the usual risk of bleeding.
Original image temporarily unavailable
Background
Traditional blood thinners are often avoided after a stroke because they carry a high risk of dangerous bleeding. Researchers have long searched for a way to prevent secondary strokes more safely without this major downside.
Details
Bayer's newly approved drug, Sunharbo, works by inhibiting a specific protein called XIa. In a large Phase 3 clinical trial involving patients who had previously suffered a stroke, the drug successfully reduced the risk of secondary strokes by 26% compared to a placebo.
Impact
This approval introduces an entirely new class of medications to cardiovascular medicine, offering doctors a safer tool to protect stroke survivors and potentially changing how long-term stroke prevention is managed.
View selection rationale
Importance 75/100
About this brief
- Content type
- Research summary
- Source type
- Publisher report
- Original source
- STAT Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.